Next Thursday, October 14, we will hold a joint event between SOLACI, CACI and the Microport company on “Challenges in TAVI: Severe Coronary Disease and Coronary Occlusion”. The activity is part of the satellite events of the SOLACI-CACI 2021 Congress and, as such, will have the participation of important international and Latin American speakers. Date:...
Early detection of coronary artery disease (CAD) using computed tomography (CT) and calcium score (CAC) might help plan prevention strategies years in advance. This study used CT to determine the prevalence and characteristics of atherosclerosis in the general population. Non-contrast images were scored for CAC. After that, all images with atherosclerosis potential were assessed segment...
✔️ Watch again the session on Cardiovascular Disease Management and Cath Lab During the COVID-19 Pandemic in the SOLACI-CACI 2021 Congress. 👨🏫 Program: 04:55 – Thromboembolic Complications in COVID – José Ceresetto 27:59 – Global Registry of Acute Myocardial Infarction of Primary PCI in COVID Era – Giuseppe De Luca 53:36 – Infectious Disease Care in...
After Transcatheter Aortic Valve Replacement (TAVR) acute coronary syndromes (ACS) are rare and mostly present as non-ST elevation events. In this context, the few ST elevation events have bad prognosis, with close to 30% mortality at 30 days. This study included patients undergoing TAVR between 2012 and 2017 admitted for acute coronary syndrome during followup. ...
Treating patients with functional stress test induced ischemia and non-obstructive coronary artery disease (INOCA) is complex and often frustrating. The multifactorial nature of this disease in addition to the complex physiopathological relationship between angina and ischemia turn these patients into a real headache for cardiologists. The CIAO-ISCHEMIA was recently published in Circulation and was designed...
Valvular heart disease management guidelines were updated last week by the AHA and the ACC. The last complete version had been published in 2014; therefore many of its recommendations have become obsolete before the latest evidence. The studies that made the FDA approve TAVI for low-risk patients are probably the most important incorporations. They also...
Evolocumab, a PCSK9 inhibitor, has shown significant reduction of complex coronary disease requiring revascularization (be it PCI or CABG). Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors induce plaque regression and could eventually reduce the risk of coronary revascularization, especially complex revascularization. The FOURIER study randomized 27564 patients with stable CAD already on statins to evolocumab...
According to this new document recently published in JACC, a computerized tomography (CT) coronary angiography should be the first study done to diagnose a stable coronary artery disease. A multidisciplinary group of experts recommends using computerized tomography as first-line diagnosis in stable patients. According to these professionals, guidelines should be updated soon. Given the accruing...
The new European guidelines on NON-ST-segment elevation acute coronary syndromes (NSTE ACS) were presented virtually during the European Society of Cardiology 2020 Congress (ESC 2020) and published in Eur Heart J. This document includes news regarding a more agile infarction diagnosis, the use of non-invasive imaging, the simplification of anticoagulant therapy, infarction with normal coronary arteries,...
According to this new study, colchicine offers some benefit to patients with chronic ischemic heart disease. Similar to COLCOT, this is the second large randomized study with results confirming the inflammatory hypothesis. Colchicine taken at a daily dose of 0.5 mg reduces cardiovascular events in patients with stable coronary disease, according to data from the LoDoCo2...